logo
Share SHARE
FONT-SIZE Plus   Neg

Sanofi Q1 Profit Rises; Backs 2012 Business EPS View - Quick Facts

Sanofi (SNY,SNYNF.PK) posted first quarter net income attributable to shareholders of 1.83 billion euros or 1.38 euros per share, up from 1.22 billion euros or 0.93 euros per share a year ago.

Business earnings per share for the quarter were 1.85 euros, 11.4% higher than the year ago quarter. Business EPS was up 7.2% at constant exchange rates.

Net sales reached 8.511 billion euros, up 9.4% on a reported basis from the prior-year quarter. At constant exchange rates, and adjusting for changes in the scope of consolidation, primarily the consolidation of Genzyme, net sales decreased 0.6%.

Commenting on the Group's performance in Q1 2012, Sanofi Chief Executive Officer, Christopher Viehbacher said,

"During the first quarter, our Business EPS grew by 7.2%. This strong performance was driven by Genzyme, our growth platforms, and cost savings. This quarter also reflects the production recovery of Genzyme with the first shipment of Fabrazyme® produced in Framingham in March.

In addition, we have submitted three new products to regulatory authorities, and released impressive clinical results for our anti-PCSK9 agent and for Lemtrada at recent medical congresses. Although as expected, Plavix will lose exclusivity in May in the U.S., the strong underlying performance of the business is consistent with our medium term growth outlook".

Taking into account the loss of Plavix and Avapro exclusivity in the U.S., the performance of growth platforms, contribution from Genzyme and cost control as well as other generic competition, 2012 business EPS is still targeted to be 12% to 15% lower at constant exchange rates than 2011, barring unforeseen adverse events.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Denver, Colorado based low-cost carrier Frontier Airlines will expand its services to 21 cities. The airline which serves 80 cities in the U.S., Mexico and the Dominican Republic is planning to add 85 new routes. Abbott Laboratories (ABT) reported a profit for the second-quarter 2017 declined about 54.1 percent from last year, hurt by higher costs. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. Abbott raised its full-year 2017 earnings per share guidance range. Consumer goods giant Unilever plc reported Thursday higher profit in its first half, with increased sales and margin. Looking ahead, the company said it is on track for another year of underlying sales growth ahead of markets.
comments powered by Disqus
Follow RTT